🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

RET fusion+ NSCLC tumors express membrane targets that could offer potential new therapeutic avenues, according to a new JAMA Oncology study using Caris' large-scale whole transcriptome data. Read more: ow.ly/C4kp50W77Vb #lungcancer

MI Cancer Seek offers a new approach to profiling solid tumors using both WES & WTS technologies. FDA-approved for molecular profiling of solid tumors in adult & pediatric (ages 1-22) patients. Learn more & view important product info: ow.ly/xK4I50W95HZ

Today, Caris Life Sciences announced the pricing of its initial public offering. Learn more: ow.ly/b1OC50WbbVx

Health care company Caris Life Sciences listing on the Nasdaq today. CEO David Halbert discusses the business ahead of its IPO: cnb.cx/4n7MM2U

🔬 Precision medicine. Real world impact. Welcome to Nasdaq, Caris Life Sciences! 🤝

A milestone moment. Join Caris as we ring the Nasdaq Opening Bell, launching the next chapter in precision medicine and molecular science innovation. Caris Founder, Chairman and CEO, David Dean Halbert reflects on a journey.

This morning, we rang the Opening Bell at the Nasdaq. It's more than a celebration; it’s a recognition of Caris' unwavering commitment to advancing the field of precision medicine and improving patient outcomes through innovative molecular science and artificial intelligence.

🧫Where molecular science meets artificial intelligence. 🤖 👏 Let’s go, Caris Life Sciences!

⚡ Officially #NasdaqListed: Caris Life Sciences is now trading under $CAI! 🥳

Caris Life Sciences is now officially trading on Nasdaq under CAI. This marks a major milestone as Caris takes another step forward in our mission to advance precision medicine and improve patient lives. Learn more: ow.ly/KOk550WbPF5 $CAI

Caris Life Sciences has reached a major milestone that not only reflects the dedication of our teams and partners but also the impact we're making in patients' lives. From pioneering molecular profiling to leading the charge in precision oncology, we're setting new standards in

Dr. David Spetzler, President of Caris Life Sciences, joined OncoDaily TV during #ASCO25 to discuss how AI and molecular data are advancing precision oncology. Watch now: ow.ly/o9iz50We1oa

Caris Life Sciences Founder, Chairman and CEO David Halbert highlights what's in store for the company's future and how this milestone will impact our mission to improve the human condition.

Empower others with your journey! Has Caris testing been part of your cancer story? Sharing your experiences can offer hope and inspiration to those who need it most. Your journey matters, make it known: ow.ly/m52Q50VuTEy

Join us for a webinar discussing homologous recombination deficiency (HRD) testing as an increasingly important tool in guiding PARP inhibitor therapy for ovarian cancer. Register Now: ow.ly/R5eW50WjeYB

July is Sarcoma Awareness Month. Caris Life Sciences supports physicians with molecular insights to better understand and treat rare, complex sarcomas. Learn more: ow.ly/PwfI50WjK4a